An NH2-terminal truncated cytochrome P450 CYP3A4 showing catalytic activity is present in the cytoplasm of human liver cells

Experimental and Molecular Medicine

Volumn 40, Issue 2, 2008, Pages 254-260

  Jeon, Songhee ^b   Kim, Keon Hee ^c   Yun, Chul Ho ^c   Hong, Boo Whan ^d   Chang, Yoon Seok ^e   Han, Ho Seong ^f   Yoon, Yoo Seok ^f   Choi, Won Bum ^a   Kim, Soyun ^a   Lee, Ai Young ^a  

^a Dongguk University College of Medicine   (South Korea)

^b Dongguk University   (South Korea)

^c Chonnam National University   (South Korea)

^d Eulji University School of Medicine   (South Korea)

^e Department of Internal Medicine ^*

^f Seoul National University Bundang Hospital   (South Korea)

Author keywords

Cytochrome P 450 CYP3A; Cytoplasm; Enzymology; Microsomes, liver

Indexed keywords

CYTOCHROME P450 3A4; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; CATALYSIS; CELL LINE; CHEMISTRY; ENZYMOLOGY; LIVER MICROSOME; METABOLISM; WESTERN BLOTTING;

BLOTTING, WESTERN; CATALYSIS; CELL LINE; CYTOCHROME P-450 CYP3A; CYTOPLASM; HUMANS; MICROSOMES, LIVER;

EID: 44349132741     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2008.40.2.254     Document Type: Article

References (31)

1. Alston K, Robinson RC, Park SS, Gelboin HV, Friedman FK. Interactions among cytochromes P-450 in the endoplasmic reticulum. Detection of chemically cross-linked complexes with monoclonal antibodies. J Biol Chem 1991;266:735-9
2. Black SD, Coon MJ. Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region. J Biol Chem 1982;257:5929-38
3. Columbano A, Shinozuka H. Liver regeneration versus direct hyperplasia. FASEB J 1996;10:1118-28
4. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985;260:9057-67
5. Enoch HG, Strittmatter P. Cytochrome b5 reduction by NADPH-cytochrome P-450 reductase. J Biol Chem 1979;254:8976-81
6. Farber E, Sarma DSR. Biology of disease. Hepatocarcinogenesis: a dynamic cellular perspective. Lab Investig 1987;56:4-22
7. Guengerich FP. Analysis and characterization of enzymes. In Principles and Methods of Toxicology (Hayes AW, ed), 3rd Ed, 1994, 1259-313, Raven Press, Ltd, New York
8. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17
9. Hanna M, De Biasi V, Bond B, Salter C, Hutt AJ, Camilleri P. Estimation of the partitioning characteristics of drugs: a comparison of a large and diverse drug series utilizing chromatographic and electrophoretic methodology. Anal Chem 1998;70:2092-9
10. Harvey JL, Paine AJ, Maurel P, Wright MC. Effect of the adrenal 11-beta-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4. Drug Metab Dispos 2000;28:96-101
11. Jaenicke R. Protein folding: local structures, domains, subunits, and assemblies. Biochemistry 1991;30:3147-61
12. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-98
13. Kim KH, Ahn T, Yun CH. Membrane properties induced by anionic phospholipids and phosphatidylethanolamine are critical for the membrane binding and catalytic activity of human cytochrome P450 3A4. Biochemistry 2003;42:15377-87
14. Kirby GM, Wolf CR, Neal GE, Judah DJ, Henderson CJ, Srivatanakul P, Wild CP. In vitro metabolism of aflatoxin B1 by normal and tumorous liver tissue from Thailand. Carcinogenesis 1993;14:2613-20
15. Komatsu T, Yamazaki H, Asahi S, Gillam EM, Guengerich FP, Nakajima M, Yokoi T. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos 2000;28:1361-8
16. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, Tanaka K, Shuda M, Yamamoto M. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999;59:4990-6
17. Lee SJ, Lee SS, Jeong HE, Shon JH, Ryu JY, Sunwoo YE, Liu KH, Kang W, Park YJ, Shin CM, Shin JG. The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab Dispos 2007;35:2095-101
18. Mochizuki J, Murakami S, Sanjo A, Takagi I, Akizuki S, Ohnishi A. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:1191-7
19. Mori Y, Niwa T, Yamazaki H, Nii H, Toyoshi K, Hirano K, Sugiura M. Influence of microsomal and cytosolic fractions from the liver of 4 animal species and man on the mutagenicity of carcinogenic aminoazo dyes and nature of the mutagenicity-enhancing factor in the cytosol from rat liver. Chem Pharm Bull 1984;32:3641-50
20. Neve EP, Ingelman Sundberg M. A soluble NH(2)-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria(1). FEBS Lett 1999;460:309-14
21. Omura T, Sato R The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-8
22. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000;10:373-88
23. Paine MF, Schmiedlin Ren P, Watkins PB. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 1999;27:360-4
24. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413-580
25. Sakaguchi M, Mihara K, Sato R. Signal recognition particle is required for co-translational insertion of cytochrome P-450 into microsomal membranes. Proc Natl Acad Sci USA 1984;81:3361-4
26. Schenkman JB, Jansson I. Interactions between cytochrome P450 and cytochrome b5. Drug Metab Rev 1999;31:351-64
27. Shimada T, Misono KS, Guengerich FP. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 1986;261:909-21
28. Shin A, Kang D, Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Yoo KY. Cytochrome P450 1A1 (CYP1A1) polymorphisms and breast cancer risk in Korean women. Exp Mol Med 2007;39:361-6
29. Szczesna-Skorupa E, Straub P, Kemper B. Deletion of a conserved tetrapeptide, PPGP, in P450 2C2 results in loss of enzymatic activity without a change in its cellular location. Arch Biochem Biophys 1993;304:170-5
30. White RE, Coon MJ. Oxygen activation by cytochrome P-450. Annu Rev Biochem 1980;49:315-56
31. Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, Yokoi T. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b (5) in bacterial membranes. Drug Metab Dispos 1999;27:999-1004